"Administrative offices for Harris Health System"

During the past decade, Harris Health System-Smith Clinic conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 4 clinical trials were completed, i.e. on average, 23.5% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 3 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Harris Health System-Smith Clinic" #1 sponsor was "Baylor College of Medicine" with 5 trials, followed by "Michelle S Ludwig" with 2 trials sponsored, "Anthony Costales, MD" with 1 trials sponsored, "Baylor Breast Care Center" with 1 trials sponsored and "Dana-Farber Cancer Institute" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Harris Health System-Smith Clinic" #1 collaborator was "GlaxoSmithKline" with 2 trials as a collaborator, "Center for Cell and Gene Therapy, Baylor College of Medicine" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Harris County Hospital District" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Harris Health System-Smith Clinic" are "Breast Cancer" (4 trials), "Triple Negative Breast Cancer" (2 trials), "B-cell Lymphoma" (1 trials), "Bladder Cancer" (1 trials) and "Breast Cancer Female" (1 trials). Many other conditions were trialed in "Harris Health System-Smith Clinic" in a lesser frequency.

Most popular intervention types in "Harris Health System-Smith Clinic" are "Drug" (15 trials), "Biological" (2 trials), "Device" (1 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Docetaxel" (2 trials), "Leucovorin" (2 trials), "Oxaliplatin" (2 trials) and "Pembrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Harris Health System-Smith Clinic" are 15 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Harris Health System-Smith Clinic". 2 are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Harris Health System-Smith Clinic, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Harris Health System-Smith Clinic, 7 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".